Hutchmed (China) Limited has started a phase I clinical trial of its menin inhibitor HMPL-506 in patients with haematological malignancies in China. The very first patient received their initial dose on May 31, 2024. This is a stage I...
CordenPharma, a worldwide CDMO pioneer in the production of drug substances (APIs) for complex modalities, LNPs containing xRNA/xDNA, and injectable medication items, and Certest, a Spanish organization focused on the improvement of new items with...
Geron Enterprise, a business stage biopharmaceutical organization meaning to alter lives by changing the course of blood cancer, declared that the US Food and Medication Organization (FDA) has sanctioned Rytelo (imetelstat) for the treatment of...
MAIA Biotechnology Inc, a clinical-stage biopharmaceutical organization creating designated immunotherapies for cancer, declared the highlights and key accomplishments year-to-date, including late clinical advancement for lead up-and-comer THIO...
Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical firm developing cutting-edge therapeutics for the treatment of metastatic breast cancers (mBC), announced that China's National Medical Products Administration (NMPA) has approved...
During the BIO International Convention 2024 in San Diego, USA, the Department of Health – Abu Dhabi (DoH), the healthcare industry's regulator, and MSD, a top biopharmaceutical company, signed a Memorandum of Understanding (MoU). DoH and MSD...
Halozyme Therapeutics, Inc, a biopharmaceutical firm, recently made the announcement that it had been granted European Patent No. 4269578. This patent covers the Enhanze rHuPH20 product that is made using Halozyme's Enhanze manufacturing methods...
Opus Genetics, a patient-first, clinical-stage gene therapy company developing treatments for inherited retinal diseases, and the Department of Health – Abu Dhabi (DoH), the Emirate's regulator of the healthcare sector, signed a Memorandum of...
Amplitude Vascular Systems (AVS), a medical device company focused on the safe and effective treatment of severely calcified arterial disease, declared that it has received an investigational device exemption (IDE) from the United States Food and...
Orchid Pharma has secured Drugs Controller General of India (DCGI) endorsement for the manufacturing and promoting of its invented New Chemical Entity active pharmaceutical ingredient (API), enmetazobactam.DCGI has conceded consent to produce and...
, CDSCO.jpg)
